Surinder S Birring Selected Research

Chronic Cough

1/2022	Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
1/2022	Cough hypersensitivity and chronic cough.
11/2021	Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
7/2021	Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough.
1/2021	Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
1/2021	Validation of a visual analog scale for assessing cough severity in patients with chronic cough.
1/2021	Cough hypersensitivity and suppression in COPD.
12/2020	Looking ahead to novel therapies for chronic cough. Part 1 - peripheral sensory nerve targeted treatments.
10/2020	Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
1/2020	A Randomized, Controlled, Pilot Study of CPAP for Patients with Chronic Cough and Obstructive Sleep Apnea.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Surinder S Birring Research Topics

Disease

55	Cough 07/2022 - 01/2003
33	Chronic Cough 01/2022 - 01/2004
7	Sarcoidosis (Schaumann Disease) 01/2022 - 02/2016
6	Inflammation (Inflammations) 07/2022 - 12/2002
5	Asthma (Bronchial Asthma) 07/2022 - 12/2002
5	Idiopathic Pulmonary Fibrosis 10/2018 - 05/2011
4	Hypersensitivity (Allergy) 01/2022 - 10/2014
4	Chronic Obstructive Pulmonary Disease (COPD) 01/2021 - 05/2013
4	Bronchitis 01/2020 - 12/2002
3	Fatigue 01/2021 - 11/2012
3	Pulmonary Sarcoidosis 03/2020 - 01/2017
3	Lung Diseases (Lung Disease) 01/2020 - 09/2015
3	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2018 - 04/2012
3	Respiratory Tract Infections (Respiratory Tract Infection) 10/2018 - 04/2009
2	Pulmonary Hypertension 01/2022 - 07/2014
2	COVID-19 01/2021 - 01/2021
2	Pneumonia (Pneumonitis) 01/2021 - 04/2014
2	Obstructive Sleep Apnea 11/2020 - 01/2020
2	Cough-Variant Asthma 01/2020 - 01/2004
2	Dyspnea (Shortness of Breath) 10/2018 - 01/2014
2	Gastroesophageal Reflux (GERD) 07/2016 - 12/2015
2	Respiratory Hypersensitivity 07/2016 - 12/2002
2	Death (Near-Death Experience) 03/2013 - 04/2012
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2021
1	Necrosis 03/2020
1	Dysgeusia (Parageusia) 01/2020
1	Hypoxia (Hypoxemia) 10/2018
1	Multiple Sclerosis 02/2018
1	Pain (Aches) 01/2018
1	somatic cough syndrome 07/2015
1	Idiopathic Interstitial Pneumonias 07/2014
1	Stroke (Strokes) 04/2014
1	Whooping Cough (Pertussis) 01/2014
1	Headache (Headaches) 01/2014
1	Infections 11/2012
1	Nausea 11/2012

Drug/Important Bio-Agent (IBA)

11	Capsaicin (Zostrix)FDA Link 01/2021 - 02/2005
11	Antitussive Agents (Antitussives)FDA Link 01/2020 - 04/2009
8	Gabapentin (Neurontin)FDA LinkGeneric 01/2021 - 11/2012
5	GefapixantIBA 01/2022 - 01/2020
4	Purinergic P2X3 ReceptorsIBA 01/2022 - 01/2020
4	Neurotransmitter Agents (Neurotransmitter)IBA 01/2021 - 11/2012
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2018 - 01/2003
4	Pharmaceutical PreparationsIBA 01/2017 - 03/2004
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2022 - 07/2016
3	Adenosine Triphosphate (ATP)IBA 11/2021 - 07/2019
3	Oxygen (Dioxygen)IBA 01/2021 - 10/2018
3	Morphine (MS Contin)FDA LinkGeneric 01/2020 - 12/2015
3	AcidsIBA 01/2020 - 11/2014
2	Prostaglandins AIBA 01/2021 - 11/2015
2	SmokeIBA 01/2020 - 05/2013
2	Pregabalin (Lyrica)FDA Link 01/2018 - 03/2016
2	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 09/2016 - 07/2016
1	Biomarkers (Surrogate Marker)IBA 07/2022
1	Purinergic P2X ReceptorsIBA 07/2021
1	GSK2798745IBA 07/2021
1	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 01/2021
1	Opioid Analgesics (Opioids)IBA 01/2021
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2021
1	RoflumilastIBA 01/2021
1	Infliximab (Remicade)FDA Link 03/2020
1	IsoprostanesIBA 01/2020
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2020
1	Purinergic Receptors (Receptors, Purine)IBA 01/2020
1	Purinergic P2 Receptors (ADP Receptor)IBA 01/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	NitritesIBA 01/2020
1	NitratesIBA 01/2020
1	salicylhydroxamic acid (SHAM)IBA 01/2020
1	Therapeutic UsesIBA 01/2020
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2018
1	Thalidomide (Thalomid)FDA Link 10/2018
1	Opiate AlkaloidsIBA 10/2018
1	Daclizumab (Zenapax)FDA Link 02/2018
1	SodiumIBA 10/2017
1	pirfenidoneIBA 10/2017
1	TheobromineIBA 07/2017
1	Prednisone (Sone)FDA LinkGeneric 01/2017
1	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2017
1	aclidinium bromideIBA 01/2016
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2016
1	SteroidsIBA 11/2014
1	Bosentan (Tracleer)FDA Link 07/2014
1	LeukotrienesIBA 01/2014
1	Immunoglobulin G (IgG)IBA 01/2014
1	leukotriene D4 receptor (cysteinyl leukotriene receptor)IBA 01/2014
1	Pertussis ToxinIBA 01/2014
1	montelukast (Singulair)FDA Link 01/2014

Therapy/Procedure

24	Therapeutics 07/2022 - 01/2003
5	Continuous Positive Airway Pressure 11/2020 - 07/2007
4	Breathing Exercises 01/2017 - 10/2013
4	Palliative Care (Palliative Therapy) 09/2015 - 04/2012
2	Drug Therapy (Chemotherapy) 01/2020 - 01/2018
2	Language Therapy (Language Training) 12/2017 - 01/2017
1	Lung Transplantation 01/2022
1	Critical Care (Surgical Intensive Care) 01/2021
1	Biological Therapy 03/2020
1	Complementary Therapies (Alternative Medicine) 10/2018
1	Immunomodulation 02/2018
1	Ambulatory Care (Outpatient Care) 09/2013